MARIA ESCOBAR: Open Payments
NPI 1679168520 · PATERSON, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$859 in 21 payments from 7 companies in 2025. Trend: 2023 $1,574 · 2024 $704 · 2025 $859
Food & beverage: $859
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $283 |
| Neurocrine BioSciences, Inc. | 4 | $175 |
| E.R. Squibb & Sons, L.L.C. | 4 | $159 |
| Axsome Therapeutics, Inc. | 1 | $121 |
| ABBVIE INC. | 5 | $88 |
| Lundbeck LLC | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
Products named: CAPLYTA, INGREZZA, COBENFY, Auvelity, VRAYLAR, REXULTI, UZEDY.
Industry payments across NJ — which companies pay providers there.
